State Medicaid program; requiring coverage of insulin and insulin delivery systems; specifying certain covered system. Effective date. Emergency.
Summary
SB 926 would require Oklahoma’s state Medicaid program to cover insulin and insulin delivery systems when medically necessary for the management or treatment of diabetes. The bill specifically states that covered insulin delivery systems include, but are not limited to, a tubeless, wearable insulin pump that delivers insulin automatically. It also directs the Oklahoma Health Care Authority to seek any federal approval needed to carry out the new coverage requirement.
The measure is written as a new section of law to be codified in Title 63 of the Oklahoma Statutes and would take effect July 1, 2025. It also contains an emergency clause, meaning the Legislature intends for it to become effective immediately upon passage and approval rather than waiting for the normal effective date, if the emergency declaration is sustained.
Impact
If enacted, SB 926 would expand mandatory Medicaid benefits in Oklahoma by requiring coverage of insulin and insulin delivery systems for eligible enrollees when medically necessary. It would affect the Oklahoma Health Care Authority’s administration of Medicaid and could require changes to coverage policies, prior authorization rules, and reimbursement practices for diabetes-related supplies and devices. Because the bill directs the agency to seek any necessary federal approval, implementation may depend on federal Medicaid compliance or waiver/plan-amendment approval.
Sentiment
The available legislative record shows the bill was introduced and referred to the Health and Human Services Committee and then the Appropriations Committee, but there are no recorded votes or committee transcripts in the provided materials. Based on the bill’s subject matter and emergency clause, the measure appears intended as a health-access and diabetes-treatment expansion, with an emphasis on timely implementation. No explicit support or opposition is documented in the supplied context.
Contention
The main policy issue is the cost and scope of requiring Medicaid to cover insulin delivery systems, especially newer devices such as tubeless wearable insulin pumps. Potential points of contention include whether the mandate should be limited to certain devices, how “medically necessary” will be interpreted, and the fiscal impact on the Medicaid program and state budget. Another possible issue is whether federal approval will be required and how quickly the Oklahoma Health Care Authority can implement the coverage change.
Carry Over
State Medicaid program; requiring coverage of insulin and insulin delivery systems; specifying certain covered system. Effective date. Emergency.